Laboratory of Stem Cells and Neurorepair, Fundación Inbiomed, Donostia-San Sebastián, Spain.
CNS Neurol Disord Drug Targets. 2010 Nov;9(5):601-15. doi: 10.2174/187152710793361531.
Dopamine modulation of excitatory neurotransmission is critical in the control of movement, emotion and reward. In the striatum, medium size spiny neurons (MSNs) are responsible for the integration of cortical and thalamic information that flows through parallel, partly overlapping, loops and determines adequate experience-dependent responses. Dopamine acts on MSNs through two sets of G protein-coupled receptors (GPCRs), the D1-like and D2-like receptors, which can have opposing or synergistic downstream effects. Notably, these two types of striatal dopamine receptors are segregated into the striatonigral (direct) and striatopallidal (indirect) projecting neurons. Thus, dopamine receptor expression determines the morphological and functional neuronal phenotype of MSNs. Moreover, dopamine regulates glutamatergic corticostriatal transmission, critically controlling the induction of long-term potentiation and long-term depression at these synapses, regulating striatal synaptic plasticity. In addition to dopamine receptors, the induction and expression of plasticity mechanisms is regulated by other GPCRs, most importantly adenosine A₂(A) receptors, metabotropic glutamate mGluR5 receptors and endocannabinoid CB1 receptors. This review focuses on synaptic modulation and plasticity on excitatory corticostriatal synapses by GPCRs.
多巴胺对兴奋性神经递质的调节在运动、情绪和奖励的控制中至关重要。在纹状体中,中型棘突神经元(MSNs)负责整合皮质和丘脑信息,这些信息通过平行的、部分重叠的回路流动,并决定适当的经验依赖性反应。多巴胺通过两组 G 蛋白偶联受体(GPCR)作用于 MSNs,即 D1 样和 D2 样受体,它们可以产生相反或协同的下游效应。值得注意的是,这两种类型的纹状多巴胺受体被分隔到纹状体黑质(直接)和纹状体苍白球(间接)投射神经元中。因此,多巴胺受体的表达决定了 MSNs 的形态和功能神经元表型。此外,多巴胺调节谷氨酸能皮质纹状体传递,在这些突触处严格控制长时程增强和长时程抑制的诱导,调节纹状体突触可塑性。除了多巴胺受体外,其他 GPCR 还调节可塑性机制的诱导和表达,最重要的是腺苷 A₂(A)受体、代谢型谷氨酸 mGluR5 受体和内源性大麻素 CB1 受体。这篇综述重点介绍 GPCR 对兴奋性皮质纹状体突触的突触调节和可塑性。
CNS Neurol Disord Drug Targets. 2010-11
Eur J Neurosci. 2001-3
Nihon Shinkei Seishin Yakurigaku Zasshi. 1997-4
Adv Exp Med Biol. 2012
Neuroscience. 2014-9-26
Prog Neuropsychopharmacol Biol Psychiatry. 2012-1-11